Transmission-Blocking Immunity in Malaria Vaccinology

Transmission-blocking immunity represents a vital component of malaria vaccine strategy, aiming to interrupt the cycle of Plasmodium transmission from humans to mosquitoes. Unlike conventional vaccines that target pre-erythrocytic or blood stages to prevent infection or disease, transmission-blocking vaccines (TBVs) induce antibodies against sexual-stage antigens expressed in gametocytes, gametes, zygotes or ookinetes. Once ingested by the mosquito in an infectious blood meal, these antibodies inhibit parasite development in the vector, thereby reducing onward transmission. Successful TBVs must elicit high-titre, functional antibodies that retain activity in the mosquito midgut environment and are sufficiently durable to match transmission seasons. Progress in antigen discovery, structural biology and adjuvant platforms has enhanced our capacity to design and evaluate TBVs. Moreover, naturally acquired transmission-reducing immunity in endemic populations offers insight into protective epitopes and mechanisms of complement-independent parasite inhibition. As malaria elimination efforts advance, integration of TBVs with existing control tools and understanding of population-level impact become ever more pressing.

Research from Nature Portfolio

Recent studies have characterised the spectrum of naturally acquired antibodies that mediate transmission-reducing activity (TRA). One investigation profiled serum reactivity from malaria-exposed individuals against a panel of gametocyte proteins, revealing that antibodies targeting Pfs48/45, Pfs230 and several novel antigens correlate strongly with reduced mosquito infection rates. Mechanistic assays demonstrated that purified antibodies against specific epitopes exert complement-independent inhibition of parasite development in the mosquito midgut.

Another line of work has focused on antigen multimerisation to enhance immunogenicity. Fusion of the Pfs25 antigen to the IMX313 oligomerisation domain markedly increased germinal centre responses and antibody avidity when delivered as a protein-nanoparticle or via viral vectors. In preclinical models this approach generated higher titres of functional antibodies and superior TRA compared with monomeric Pfs25, underlining the promise of multimerisation technologies for TBV design.

A comparative assessment of leading sexual-stage antigens delivered by chimpanzee adenovirus and modified vaccinia Ankara vectors provided a head-to-head evaluation of Pfs25, Pfs230-C, Pfs48/45 and a midgut-binding protein. This study established a hierarchy of inhibitory efficacy across both laboratory and field parasite strains, confirming that Pfs25 and Pfs230-C induce the most robust blockade in standard mosquito-feeding assays and informing prioritisation of candidates for clinical development.

Transmission-Blocking Immunity in Malaria Vaccinology publication trend

The graph below shows the total number of articles in transmission-blocking immunity in malaria vaccinology across all publications each year (not limited to Nature Index journals).

Technical terms

Gametocyte: The sexual form of Plasmodium parasites in human blood that is infectious to mosquitoes.

Transmission-blocking vaccine (TBV): A vaccine designed to induce antibodies that prevent parasite development within the mosquito, thereby interrupting transmission.

Transmission-reducing activity (TRA): The percentage reduction in mosquito infection or oocyst intensity conferred by vaccine-induced or naturally acquired antibodies in feeding assays.

Standard membrane feeding assay (SMFA): A laboratory method in which cultured gametocytes are fed to mosquitoes through a membrane in the presence of test antibodies to measure TRA.

Multimerisation technology: A strategy that assembles multiple copies of an antigen into higher-order structures to enhance B-cell activation and antibody responses.

References

1. A randomized first-in-human Phase 1 trial of differentially adjuvanted Pfs48/45 malaria vaccines in Burkinabé adults. Journal of Clinical Investigation (2024).
2. Immunity against sexual stage Plasmodium falciparum and Plasmodium vivax parasites. Immunological Reviews (2019).
3. Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology. Scientific Reports (2016).
4. Comparative Assessment of Transmission-Blocking Vaccine Candidates against Plasmodium falciparum. Scientific Reports (2015).
5. Unravelling the immune signature of Plasmodium falciparum transmission-reducing immunity. Nature Communications (2018).